Mifepristone

Major

Mifepristone Darolutamide Nubeqa Increased CYP3A4 substrate exposure Details Mifepristone Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Mifepristone Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Mifepristone Diazepam Nasal Spray Valtoco Increased CYP3A4 substrate exposure Details Mifepristone Diazepam Rectal Diastat Increased CYP3A4 substrate exposure Details Mifepristone Digoxin Cardoxin® Increased digoxin exposure Details Mifepristone Disopyramide Norpace Increased disopyramide exposure and an increased risk of QT interval prolongation Details Mifepristone Dolasetron Anzemet An increased risk of QT interval prolongation Details Mifepristone Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Mifepristone Dolutegravir Juluca® (as a combination product containing dolutegravir, rilpivirine) Increased CYP3A4 substrate exposure Details Mifepristone Doravirine Pifeltro Increased CYP3A4 substrate exposure Details Mifepristone Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Mifepristone Elacestrant Orserdu Increased CYP3A4 substrate exposure Details Mifepristone Encorafenib Braftovi Increased encorafenib exposure, reduced miFEPRIStone exposure and an increased risk of QT interval prolongation Details Mifepristone Eravacycline Injection Xerava Increased CYP3A4 substrate exposure Details Mifepristone Erdafitinib Balversa Increased erdafitinib exposure and an increased miFEPRIStone exposure Details Mifepristone Eribulin Injection Halaven An increased risk of QT interval prolongation Details Mifepristone Esketamine Nasal Spray Spravato Increased miFEPRIStone exposure Details Mifepristone Esomeprazole Nexium Increased miFEPRIStone exposure Details Mifepristone Esomeprazole Injection Nexium Increased miFEPRIStone exposure Details Mifepristone Estradiol Delestrogen Reduced hormonal contraceptive exposure, an increased miFEPRIStone exposure and an increased hormonal contraceptives exposure Details Mifepristone Estradiol Topical Divigel Reduced hormonal contraceptive exposure, an increased miFEPRIStone exposure and an increased hormonal contraceptives exposure Details Mifepristone Estradiol Transdermal Patch Alora® Reduced hormonal contraceptive exposure, an increased miFEPRIStone exposure and an increased hormonal contraceptives exposure Details Mifepristone Famotidine Calmicid An increased risk of QT interval prolongation Details Mifepristone Famotidine Injection Calmicid An increased risk of QT interval prolongation Details Mifepristone Felbamate Felbatol An increased risk of QT interval prolongation Details Mifepristone Felodipine Plendil® Increased CYP3A4 substrate exposure Details Mifepristone Flecainide Tambocor® An increased risk of QT interval prolongation Details Mifepristone Foscarnet Injection Foscavir Increased risk of QT interval prolongation Details Mifepristone Fostamatinib Tavalisse Increased CYP3A4 substrate exposure and an increased miFEPRIStone exposure Details Mifepristone Fostemsavir Rukobia Increased risk of torsade de pointes Details Mifepristone Futibatinib Lytgobi Increased CYP3A4 substrate exposure Details Mifepristone Galantamine Razadyne An increased risk of QT interval prolongation Details Mifepristone Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation Details Mifepristone Gemifloxacin Factive An increased risk of QT interval prolongation Details Mifepristone Gilteritinib Xospata Increased CYP3A4 substrate exposure Details Mifepristone Glasdegib Daurismo Increased glasdegib exposure and an increased risk of QT interval prolongation Details Mifepristone Goserelin Implant Zoladex Increased risk of QT interval prolongation Details Mifepristone Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation Details Mifepristone Granisetron Injection Granisol An increased risk of QT interval prolongation Details